Q1 2027 Solara Active Pharma Sciences Ltd Earnings Call Transcript
Key Points
- Solara Active Pharma Sciences Ltd (BOM:541540) reported a 20% year-on-year increase in overall revenues, reaching INR384 crore.
- The company achieved its highest EBITDA and PAT in the last 18 quarters, with EBITDA up 10% year-on-year and PAT up 55% year-on-year.
- The base business revenues grew by 24% year-on-year, demonstrating strong momentum and operational execution.
- Net debt was reduced by INR135 crore during the quarter, reflecting a 22% reduction, and the company aims to further reduce it by the end of March '27.
- The company is focusing on expanding existing business, seeding new businesses, and optimizing working capital to drive sustainable profitability growth.
- The commodity Ibuprofen business continues to face profitability challenges, with an EBITDA margin of negative 12%.
- The ongoing geopolitical developments in West Asia have led to higher raw material prices, impacting cost pressures.
- Gross margins were marginally lower on a quarter-on-quarter basis due to raw material pricing and supply challenges.
- The company faces challenges in passing on increased raw material costs to customers, impacting profitability.
- The strategic review of the Ibuprofen business is still ongoing, with no definitive resolution yet, creating uncertainty.
Ladies and gentlemen, good day, and welcome to the Solara Active Pharma Sciences Limited Q1 FY27 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Thank you, Anushka. Good afternoon, and thank you all for joining us today for Solara earnings call for Q1 FY27. Today, we have with us Sandeep, MD and CEO; and Sarat, CFO of the company, to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release and the quarterly investor presentation that have been uploaded on our website as well as the stock exchange website. The transcript of this call will be available in a week's time on the company's website.
Please note that today's discussion will be forward-looking in nature and must be viewed in relation to risks pertaining to our business. After the end of the call, in case you have any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
